Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.8
3.9
Journals
Biomedicines
Special Issues
Advanced Research in Chronic Respiratory Diseases (CRDs)
share announcement

Advanced Research in Chronic Respiratory Diseases (CRDs)

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: closed (31 May 2025) | Viewed by 732

Special Issue Editor

Dr. Hung-Yu Huang

E-Mail Website
Guest Editor
Chang Gung Memorial Hospital, Taipei, Taiwan
Interests: chronic respiratory diseases; bronchiectasis; obstructive pulmonary disease (COPD)

Special Issue Information

Dear Colleagues,

Chronic respiratory diseases (CRDs) mainly affect the airways and other lung structures. Most common CRDs are chronic obstructive pulmonary disease (COPD), lung fibrosis, bronchiectasis asthma, occupational lung diseases, and pneumoconiosis. These diseases can be caused by long-term exposure to tobacco smoke or irritating gases; other risk factors include air pollution, occupational chemicals, dust, and frequent lower respiratory infections during childhood.

Identifying biomarkers, including inflammatory, image, genomics, microbiome, and molecular endotypes, holds potential to guide individualized therapies for CRD. This Special Issue aims to publish research related to various biomarkers of CRD. This Special Issue will publish full research articles, comprehensive reviews, and shorter perspective articles on all aspects related to the theme of chronic respiratory diseases. Research areas may include (but are not limited to) the following: inflammatory, image, genomics, microbiome, and molecular biomarkers.

We look forward to receiving your contributions.

Dr. Hung-Yu Huang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic respiratory failure
  • occupational lung diseases
  • obstructive pulmonary disease (COPD)
  • asthma
  • bronchiectasis
  • interstitial lung disease
  • cystic fibrosis and lung fibrosis
  • lung distraction
  • pneumoconiosis
  • lung microbiota
  • smoking

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 595 KiB  
Article
Carbon Footprint Impact, of Monoclonal Antibodies for Severe Asthma, Administered in Italy
by Diego Bagnasco, Laura Pini, Benedetta Bondi, Carola Montagnino, Elisa Testino, Veronica Capuano, Celeste Pugliaro, Luisa Brussino, Stefania Nicola, Marco Caminati, Ilaria Baiardini and Fulvio Braido
Biomedicines 2025, 13(7), 1574; https://doi.org/10.3390/biomedicines13071574 - 27 Jun 2025
Viewed by 525
Abstract
Background: Severe asthma is a respiratory condition, involving treatments (i.e., inhaled steroids, systemic steroids, hospitalization) capable of increasing significant carbon footprint, raising concerns about environmental sustainability in healthcare. Sustainable healthcare policies and use of environmentally friendly treatment options are crucial in balancing [...] Read more.
Background: Severe asthma is a respiratory condition, involving treatments (i.e., inhaled steroids, systemic steroids, hospitalization) capable of increasing significant carbon footprint, raising concerns about environmental sustainability in healthcare. Sustainable healthcare policies and use of environmentally friendly treatment options are crucial in balancing effective asthma management with climate responsibility. Objectives: With this manuscript, we want to assess the impact, in terms of CO2 production, of patients suffering from severe asthma and treated with biological drugs, to show the reduction in carbon footprint after the use of these drugs compared to the time when they were not prescribed. We analyzed data from three studies, all conducted in real life in Italy, of patients treated with mepolizumab, benralizumab and dupilumab, for the control of severe asthma. Methods: Data on number of exacerbations and hospitalizations, systemic corticosteroids (CS) cycles and their dose, were collected by three already published real-life trials, on the above-mentioned biologics, and used to calculate carbon footprint impact before and after biological therapy. For the mepolizumab study, the data collected referred to patients who started the drug between June 2017 and January 2019; for dupilumab, there were no age limits with patients enrolled between December 2019 and July 2020, whereas in the benralizumab study, all patients had to be over 18 years old. The statistical analysis was performed with Shapiro–Wilk test, t test and Cohen’s test. Results: The use of biologic drugs showed a significant reduction in CO2 production after the introduction of these therapies, mainly secondary to a reduction in exacerbations, hospitalizations and CS use. In numerical terms, an average reduction of 75% in CO2 production, per patient, is shown. Conclusions: Disease control, clinical remission of disease, in patients with severe asthma is certainly a determining factor in assessing the effectiveness of a treatment. Provided these goals are achieved, biological drug therapy has also proved to be particularly virtuous from the fundamental environmental point of view, allowing a significant reduction in CO2 production for the management of these patients. Full article
(This article belongs to the Special Issue Advanced Research in Chronic Respiratory Diseases (CRDs))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop